Evaluation of safety and efficacy of T1h (anti-CD6) as monotherapy and in combination with methotrexate in patients with rheumatoid arthritis

Trial Profile

Evaluation of safety and efficacy of T1h (anti-CD6) as monotherapy and in combination with methotrexate in patients with rheumatoid arthritis

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Itolizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2013 Status changed from recruiting to suspended, as per Cuban Clinical Trial Registry record
    • 13 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top